Nephrocare Health Services Ltd. IPO

Apply 0
Avoid 0

Don't Miss It! Mark Your Calender Now:


Nephrocare Health Services Ltd. is India’s and Asia’s largest dialysis services provider, offering comprehensive dialysis care through a wide clinic network. The company provides end-to-end renal care—including haemodialysis, home dialysis, mobile dialysis, and wellness support—making it the largest player in India across patients served, treatments performed, clinics, cities covered, revenue and EBITDA (FY 2025).

Business Model

Nephrocare operates an asset-light and capital-efficient model, with:

i) 52.41% of clinics under revenue-sharing arrangements, requiring minimal upfront capex.
ii) Rapid breakeven for brownfield and captive clinics—typically 3–4 months.
iii) Greenfield clinics breakeven in 12 months.

The mixed model of greenfield, brownfield, hospital partnerships, and PPPs has enabled rapid nationwide and international expansion

Scale & Market Leadership

Nephrocare is India’s largest dialysis services provider—4.4× bigger than the next organized player by operating revenue—and also the largest in Asia and 5th largest globally based on treatments performed in FY 2025. In FY 2025, the company served 29,281 patients and delivered 28.85 lakh treatments, accounting for nearly 10% of India’s dialysis patients. As of September 30, 2025, Nephrocare had already served 31,046 patients with 15.91 lakh treatments.

Extensive Clinic Network

Nephrocare operates:

– 519 clinics globally, including 51 international clinics across Philippines (41), Nepal (6), Uzbekistan (4).

– Most widely distributed network in India with presence across 288 cities, 21 states, and 4 union territories.

– 77.35% clinics located in Tier II & Tier III cities, reinforcing accessibility in underserved regions.

Service Philosophy: Accessibility, Quality & Value

Nephrocare’s service philosophy centers on Accessibility, Quality, and Value. It ensures wide access through a pan-India network of in-hospital clinics, standalone centers, PPP units, and services like holiday dialysis and dialysis-on-wheels. Quality is maintained through standardized, protocol-driven care using its proprietary RenAssure® Protocols. Its asset-light, scalable model enables cost-efficient operations and rapid expansion while delivering high-value dialysis care.

Objects of the Nephrocare Health Services Ltd. IPO:

Company proposes to utilize the Net Proceeds towards funding the following objects: 1. Capital expenditure for opening new dialysis clinics in India (₹ 129.1 cr) 2. Pre-payment or repayment of certain borrowings (₹ 135.9 cr) 3. General corporate purposes.

Nephrocare Health Services Ltd. IPO Details:

Open Date: Dec 10 2025
Close Date: Dec 12 2025
Total Shares: 1,89,35,819
Face Value: ₹ 2 Per Equity Share
Issue Type: Book Building
Issue Size: 871.05 Cr.
Lot Size: 32 Shares
Issue Price: ₹ 438 - 460 Per Equity Share
Listing At: NSE,BSE
Listing Date: Dec 17 2025

Promoters And Management:

1. Vikram Vuppala, Founder, Chairman & Managing Director, has been associated with the Company since 2009. He oversees global expansion, partnerships, and governance. An IIT Kharagpur graduate with an MBA from Chicago Booth, he has 21+ years of experience and has worked with McKinsey, ZS Associates, and Abbott. 2. Vishal Vijay Gupta, Non-Executive Nominee Director since 2014, is a Chartered Accountant with a PGDM from IIM Calcutta. He has 20+ years of experience in investments and private equity and currently serves as Managing Director at BVP India Investors. 3. Gaurav Sharma, Non-Executive Nominee Director since 2019, holds a B.Tech from IIT Delhi and an MBA from Wharton. With 18+ years of investment and private equity experience, he has previously worked with IDFC Alternatives, Providence Equity, and Deutsche Bank and currently heads India investment business at Investcorp India.

Financials of Nephrocare Health Services Ltd. IPO:

Particulars 6M FY2025-26 FY 2024-25 FY 2023-2024 FY 2022-2023
Revenue from Operations (Cr) 473.50 755.80 566.10 437.20
EBITDA (Cr) 110.30 166.60 99.60 48.50
EBITDA Margins 23.30% 22.05% 17.60% 11.11%
PAT (Cr) 14.2 67 35 -11.7
PAT Margins 3.00% 8.88% 6.21% -2.70%
ROCE 11.99% 18.68% 10.00% 0.44%
D/E Ratio 0.28 0.37 0.57 0.51
OPerating Cash Flow 38.1 135.3 72.2 11.2

Comparison With Peers:

Companies Revenue (in cr) EBITDA Margins PAT Margins ROCE D/E Ratio MCap (in cr) P/E
Nephrocare Health Services Limited 755.80 22.05% 8.88% 18.68% 0.37 Updated Soon Updated Soon
Jupiter Life Line Hospitals 1262 24% 15.37% 18.00% 0.28 9485 48
Rainbow Children Hospital 1516 33% 16.09% 18.70% 0.54 13688 53.9
Dr. Agarwal’s Healthcare 1711 27% 6.4 9.90% 0.51 16128 139
Dr. Lal Path Labs 2461 28% 19.90% 28.99% 0.07 25211 47
Metropolis Healthcare 1331 23% 10.96% 14.70% 0.14 10018 63.3
Vijaya Diagnostics 681 40% 19.90% 20.90% 0.42 10216 67

Registrar of Nephrocare Health Services Ltd. IPO:

  1. Kfin Technology Private Limited

Discussion on Nephrocare Health Services Ltd. IPO:

Leave a Reply